{"id":4850,"date":"2020-02-27T07:05:55","date_gmt":"2020-02-27T13:05:55","guid":{"rendered":"https:\/\/ibio.org\/?p=4850"},"modified":"2020-03-05T07:06:41","modified_gmt":"2020-03-05T13:06:41","slug":"abbvie-statement-on-coronavirus-and-lopinavir-ritonavir","status":"publish","type":"post","link":"https:\/\/ibio.org\/abbvie-statement-on-coronavirus-and-lopinavir-ritonavir\/","title":{"rendered":"AbbVie Statement on Coronavirus and lopinavir\/ritonavir"},"content":{"rendered":"<p>As one of the first pharmaceutical companies to respond to the emerging novel coronavirus (COVID-19) crisis, in late January, AbbVie donated a supply of Kaletra\/Aluvia (lopinavir\/ritonavir)\u00a0to the Chinese health authorities for use as an experimental treatment option.<\/p>\n<p>We are\u00a0committed to making a meaningful contribution to efforts to combat this global public health crisis and continue to address urgent supply needs in several countries impacted by the outbreak.\u00a0\u00a0Our company is also working closely with the World Health Organization (WHO) and global health authorities to respond to the needs of patients impacted by\u00a0COVID-19.\u00a0 Specifically,\u00a0we have taken action\u00a0through the provision of\u00a0Kaletra\/Aluvia as an experimental option for treatment of COVID-19, and through coordination with WHO, US NIH, and our industry partners.\u00a0\u00a0Our company is also exploring a potential research collaboration with the Innovative Medicines Initiative (IMI), which is exploring multiple potential COVID-19 treatment options.<\/p>\n<p><a href=\"https:\/\/www.abbvie.com\/content\/dam\/abbvie-dotcom\/uploads\/PDFs\/factsheet-coronavirus-030420.pdf\">View Factsheet<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>As one of the first pharmaceutical companies to respond to the emerging novel coronavirus (COVID-19) crisis, in late January, AbbVie donated a supply of Kaletra\/Aluvia (lopinavir\/ritonavir)\u00a0to the Chinese health authorities for use as an experimental treatment option. We are\u00a0committed to making a meaningful contribution to efforts to combat this global public health crisis and continue [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":4843,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[337],"tags":[340,339],"class_list":["post-4850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid","tag-abbvie","tag-coronavirus"],"_links":{"self":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/4850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/comments?post=4850"}],"version-history":[{"count":0,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/4850\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media\/4843"}],"wp:attachment":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media?parent=4850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/categories?post=4850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/tags?post=4850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}